Follicum AB receives Notice of Allowance from the U.S. Patent Office for Enhanced Protection of Product Candidate FOL-005

July 31, 2018

Follicum AB receives Notice of Allowance from the U.S. Patent Office for Enhanced Protection of Product Candidate FOL-005

Follicum AB (“Follicum”) announces that the U.S. Patent Office (USPTO) has issued a Notice of Allowance for their patent application 15/184,290 which is the company’s second, follow-up application which when granted confers expanded protection for Follicum’s product candidate FOL-005.

Follicum has already an approved US patent in this patent family, specifically covering FOL-005. Follicum has subsequently submitted a follow-up application, called Continuing Patent Application, which extends the protection around FOL-005 for which Follicum now has received a Notice of Allowance. Notice of Allowance means that the US patent office, intends to grant the company’s patent application after any administrative action by both parties has been implemented. When the patent is granted it can be kept in force until 2032.

CEO Jan Alenfall comments
– We are very pleased to receive this Notice of Allowance which is an important step in our global patent strategy. It provides additional commercialization opportunities in the United States which is one of the largest markets for Follicum, and an extended product protection for our drug candidate is thus extremely important.

About FOL-005
FOL-005 is a modified short version of the endogenous protein, osteopontin. In a completed Phase I / IIa study, FOL-005 proved to be an effective and safe treatment. Even after three months of treatment, three out of four responded with increased hair growth. Currently, a Phase IIa study is underway to investigate the safety and efficacy after treatment with different doses of the drug candidate FOL-005 or placebo for three months. In this study, patients receive injections into the scalp three times a week. Patient recruitment was completed in early June 2018 and the study is expected to be finished and top-line data presented at the end of 2018.

For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97

This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 31 of July 2018.

About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011 and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight Stock Market.

Open Press release